Cancer is one of the most significant health challenges we face today. As a forensic health practitioner, I understand the deep concerns many people have about cancer, especially when it comes to understanding how our daily habits may increase or decrease our risk. I am here to guide you through these complex concerns, offering personalised 1-2-1 advice and practical strategies to improve your metabolic health. I encourage you to book a call with me for more in-depth insights tailored to your unique health profile.
Research shows that Cancer remains a leading cause of illness and death worldwide, with more than 20 million new cases and nearly 10 million deaths each year. The numbers are staggering, and they continue to rise. Recent data shows an alarming increase in both cancer incidence and mortality globally, highlighting the need for effective prevention strategies . Cancer is also a major contributor to claims in Life & Health Insurance, particularly in critical illness, life, and disability insurance policies.
According to the latest research modern lifestyles have led to an increase in metabolic diseases, including insulin resistance, type 2 diabetes (T2D), and obesity. These conditions are strongly linked to an increased risk of several types of cancer, including those of the endometrium, pancreas, liver, and more . The connection between these metabolic risks and cancer is well-established, with scientific evidence suggesting that high insulin levels, visceral adiposity, and physical inactivity are significant contributors to cancer development.
Further research shows that Metabolic syndrome (MetS), which includes high fasting blood sugar, elevated blood pressure, obesity, and high blood lipids, is increasingly recognised as a significant risk factor for cancer. The risk can vary depending on factors such as sex, ethnicity, and menopausal status . For instance, women with MetS may have a higher risk of certain cancers, such as colorectal cancer, especially before menopause.
There is significant research that shows that being overweight or obese is now linked to over 30 types of cancer, far more than previously thought. Studies indicate that four out of ten cancer cases could be attributed to excess weight, underscoring the importance of maintaining a healthy weight.
Insulin resistance and T2D are particularly concerning when it comes to cancer risk. Research has shown that individuals with markers of insulin resistance are at a higher risk of developing various cancers, including colorectal, breast, and pancreatic cancer . It’s crucial to address insulin resistance early on, as it is a root cause of many metabolic health issues that can lead to cancer.
Diet plays a pivotal role in preventing metabolic disorders that increase cancer risk. However, it’s not just about managing insulin resistance; certain foods themselves may contribute to cancer. For example, diets high in ultra-processed foods are linked to an increased risk of several cancers, including those of the mouth, throat, and colorectum . While the evidence around red meat and cancer risk is still debated, it’s clear that a balanced, nutrient-rich diet is crucial for cancer prevention.
The relationship between metabolic health and cancer is complex, involving multiple biological mechanisms. Insulin resistance and hyperinsulinaemia are central, promoting cell growth and survival, which can lead to cancer. Obesity further exacerbates these risks by creating a low-grade inflammatory state that can promote cancer development . Understanding these mechanisms underscores the importance of a holistic approach to metabolic health.
Physical inactivity is another major modifiable risk factor for cancer. Regular physical activity can significantly reduce the risk of various cancers, including breast, colorectal, and endometrial cancers. Exercise improves insulin sensitivity, reduces inflammation, and enhances the immune system, making it a powerful tool in cancer prevention.
There’s an alarming trend in the rise of early-onset cancers, particularly among younger populations. While the exact causes are still being investigated, metabolic risks such as obesity, insulin resistance, and physical inactivity are believed to play a significant role. This makes addressing these risks even more critical.
The best way to combat cancer is to prevent it from developing in the first place. By improving metabolic health through diet, exercise, and potentially even pharmacological interventions, we can reduce cancer risk significantly. For insurers, this presents an opportunity to lower cancer-related claims by supporting initiatives that promote metabolic health.
If you’re concerned about your metabolic health and its impact on your cancer risk, now is the time to take action. Helen is available to discuss your unique health situation and guide you through the steps you can take to reduce your risk. Book a call today to start your journey towards better health and peace of mind.
References
1 https://www.who.int/news-room/fact-sheets/detail/cancer
2 Global Burden of Disease 2019 Cancer Collaboration. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420–444
3 https://www.swissre.com/reinsurance/life-and-health/l-h-risk-trends/potential-of-cancer-prevention.html
4 Chiefari E, Mirabelli M, La Vignera S, Tanyolaç S, Foti DP, Aversa A, Brunetti A. Insulin Resistance and Cancer: In Search for a Causal Link. International Journal of Molecular Sciences. 2021; 22(20):11137.
5 Fang X, Wei J, He X, Lian J, Han D, An P, Zhou T, Liu S, Wang F, Min J. Quantitative association between body mass index and the risk of cancer: A global Meta-analysis of prospective cohort studies. Int J Cancer. 2018 Oct 1;143(7):1595-1603.
6 Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K; International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer–Viewpoint of the IARC Working Group. N Engl J Med. 2016 Aug 25;375(8):794-8.
7 McTiernan A, Friedenreich CM, Katzmarzyk PT, Powell KE, Macko R, Buchner D, Pescatello LS, Bloodgood B, Tennant B, Vaux-Bjerke A, George SM, Troiano RP, Piercy KL; 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE. Physical Activity in Cancer Prevention and Survival: A Systematic Review. Med Sci Sports Exerc. 2019 Jun;51(6):1252-1261.
8 Global Burden of Disease 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10352):563-591.
9 Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord. 2009 Aug;7(4):279-88.
10 Sun M, Da Silva M, Bjørge T, Fritz J, Mboya I, Häggström C, Stocks T. Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden: a pooled cohort study aiming to identify further obesity-related cancers. EASO 2024, 31st European Congress on Obesity, Venice, AS09.04.
11 Sun M, Fritz J, Häggström C, Bjørge T, Nagel G, Manjer J, Engeland A, Zitt E, van Guelpen B, Stattin P, Ulmer H, Stocks T. Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study. J Natl Cancer Inst. 2023 Apr 11;115(4):456-467.
12 Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer. 2020 Nov;20(11):629-644.
13 Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E, Brunetti A. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174.
14 Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul;33(7):1674-85.
15 Zhu B, Qu S. The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms. Front Endocrinol (Lausanne). 2022 Feb 11;13:800995.
16 Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009 Sep;52(9):1766-77.
17 Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;2012:413782. doi: 10.1155/2012/413782. Epub 2012 Jun 5.
18 Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018 Feb;6(2):95-104. Corrected and republished in: Lancet Diabetes Endocrinol. 2018 Jun;6(6):e6-e15.
19 Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, Gregg EW. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021 Mar;9(3):165-173. doi: 10.1016/S2213-8587(20)30431-9. Epub 2021 Feb 4. PMID: 33549162; PMCID: PMC7886654.
20 Zhong W, Mao Y. Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes. JAMA Oncol. 2022;8(9):1356-1358. doi:10.1001/jamaoncol.2022.2960
21 Mili N, Paschou SA, Goulis DG, Dimopoulos MA, Lambrinoudaki I, Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021 Dec;74(3):478-497. doi: 10.1007/s12020-021-02884-x. Epub 2021 Oct 8. PMID: 34625915.
22 Rahman I, Athar MT, Islam M. Type 2 Diabetes, Obesity, and Cancer Share Some Common and Critical Pathways. Front Oncol. 2021 Jan 20;10:600824. doi: 10.3389/fonc.2020.600824. PMID: 33552973; PMCID: PMC7855858.
23 Chang K, Gunter MJ, Rauber F, Levy RB, Huybrechts I, Kliemann N, Millett C, Vamos EP. Ultra-processed food consumption, cancer risk and cancer mortality: a large-scale prospective analysis within the UK Biobank. EClinicalMedicine. 2023 Jan 31;56:101840. doi: 10.1016/j.eclinm.2023.101840. PMID: 36880051; PMCID: PMC9985039.
24 Isaksen IM, Dankel SN. Ultra-processed food consumption and cancer risk: A systematic review and meta-analysis. Clin Nutr. 2023 Jun;42(6):919-928. doi: 10.1016/j.clnu.2023.03.018. Epub 2023 Mar 30. PMID: 37087831.
25 Morales-Berstein F et al. EPIC Network. Ultra-processed foods, adiposity and risk of head and neck cancer and oesophageal adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition study: a mediation analysis. Eur J Nutr. 2023 Nov 22. doi: 10.1007/s00394-023-03270-1. Epub ahead of print. PMID: 37989797.
26 Händel MN, Rohde JF, Jacobsen R, Heitmann BL. Processed Meat Consumption and the Risk of Cancer: A Critical Evaluation of the Constraints of Current Evidence from Epidemiological Studies. Nutrients. 2021;13(10):3601. Published 2021 Oct 14. doi:10.3390/nu13103601
27 Lescinsky H, Afshin A, Ashbaugh C, et al. Health effects associated with consumption of unprocessed red meat: a Burden of Proof study. Nat Med. 2022;28(10):2075-2082. doi:10.1038/s41591- 022-01968-z
28 Fiuza-Luces C, Valenzuela PL, Gálvez BG, Ramírez M, López-Soto A, Simpson RJ, Lucia A. The effect of physical exercise on anticancer immunity. Nat Rev Immunol. 2023 Oct 4. doi: 10.1038/s41577- 023-00943-0. Epub ahead of print. PMID: 37794239.
29 Tian et al., Rising accelerated aging in recent generations associated with elevated risk of early-onset cancers. AACR Annual Meeting 2024, https://www.abstractsonline.com/pp8/#!/20272/presentation/5074.
30 Abboud Y, Samaan JS, Oh J, et al. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018. Gastroenterology. 2023;164(6):978-989.e6. doi:10.1053/j.gastro.2023.01.022.
31 Liu J, Knezetic JA, Strömmer L, Permert J, Larsson J, Adrian TE. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin Endocrinol Metab. 2000;85(3):1232-1238. doi:10.1210/jcem.85.3.6400.
32 Chen Y, Zeng S, Jiao B, Zhang H, Li G, Zhang X, Hu X. Adherence to the Diabetes Risk Reduction Diet and Bladder Cancer Risk in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cohort. Cancer Epidemiol Biomarkers Prev. 2023 Dec 1;32(12):1726-1733. doi: 10.1158/1055-9965.EPI-23-0690. PMID: 37721479.
33 Weber DD, Aminazdeh-Gohari S, Kofler B. Ketogenic diet in cancer therapy. Aging (Albany NY). 2018 Feb 11;10(2):164-165. doi: 10.18632/aging.101382. PMID: 29443693; PMCID: PMC5842847.
34 Klement RJ. Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. Med Oncol. 2017;34(8):132. doi:10.1007/s12032-017-0991-5
35 Ludwig DS, Hu FB, Lichtenstein AH, Willett WC. Low-fat diet Redux at WHO. Am J Clin Nutr. 2023;118(5):849-851. doi:10.1016/j.ajcnut.2023.09.006
36 Courcoulas AP, Daigle CR, Arterburn DE. Long term outcomes of metabolic/bariatric surgery in adults. BMJ. 2023 Dec 18;383:e071027. doi: 10.1136/bmj-2022-071027. PMID: 38110235.
House of Evexia,
24, Railway Terrace
Rugby
Warwickshire
CV21 3LJ
